Relmada Therapeutics shares are trading higher after Jefferies upgraded the stock from Hold to Buy and raised its price target from $3.5 to $13.
Portfolio Pulse from Benzinga Newsdesk
Relmada Therapeutics shares surged after Jefferies upgraded the stock from Hold to Buy and increased its price target from $3.5 to $13.

September 17, 2024 | 12:51 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Relmada Therapeutics shares increased following Jefferies' upgrade from Hold to Buy, with a significant price target raise from $3.5 to $13.
The upgrade by Jefferies from Hold to Buy and the substantial increase in the price target from $3.5 to $13 is a strong positive signal for investors, likely leading to increased buying interest and a rise in the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100